Results 131 to 140 of about 2,521 (195)

Comparison of Substances in Combined Oral Contraceptives Used in Acne Vulgaris, Hirsutism, Migraine, and Dysmenorrhea. [PDF]

Med Sci Monit
Wójcikiewicz P, Durlej G, Satora M, Tarkowski R, Kułak K.   +4 more
europepmc   +1 more source

Contribution of the combined oral contraceptive ethinylestradiol 20 µg/dienogest 2 mg, in the treatment of mild to moderate acne vulgaris and its perceived psychological effects in young university women. [PDF]

Int J Womens Dermatol
Palacio-Cardona JJ, Caicedo-Borrero DM, Cuartas DE, Calle-Madrid C, Aristizabal-Aristizabal DM.   +4 more
europepmc   +1 more source

How We Can Optimize Dysmenorrhea Treatment: Real-World Results from a Cross-Sectional, Multi-Center Study. [PDF]

Geburtshilfe Frauenheilkd
Cirkel C, Göbel H, Göbel C, Alkatout I, Brüggemann N, Kaiser AK, Minnerup J, Rody A, Cirkel A.   +8 more
europepmc   +1 more source

Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial. [PDF]

Adv Ther
Kikuno K, Asada R, Ishihara T, Morishige KI, Chikazawa K, Furui T, Isobe M.   +6 more
europepmc   +1 more source

Case Report: Long-term maintenance of GnRH-a combined with dienogest for thoracic endometriosis syndrome. [PDF]

Front Med (Lausanne)
Tang H, Jia Q, Chen W, Wei W, Ma Z, Chen J.   +5 more
europepmc   +1 more source

Deeply Infiltrating Endometriosis (DIE) No More: Dienogest as a Game Changer in Rectovaginal Endometriosis. [PDF]

Cureus
Tan AWM, Ho XY, Lee JCS.
europepmc   +1 more source

Hormonal and complimentary treatments for endometriosis: a narrative review. [PDF]

Gynecol Pelvic Med
Onishi A, Benetti-Pinto CL, Yela DA.
europepmc   +1 more source

Dienogest.

Australian prescriber, 2015
openaire   +1 more source

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial. [PDF]

JMIR Res Protoc
Kikuno K, Asada R, Ishihara T, Bomoto Y, Murase S, Ueda Y, Shiga T, Hayasaki Y, Furui T, Matsuzaki S, Takemura M, Matsunami K, Kubo M, Ito N, Isobe M, Morishige KI.   +15 more
europepmc   +1 more source

Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial. [PDF]

EClinicalMedicine
Lobo R, Angulo A, Muñoz A, Colli E, Escobar-Morreale HF, Luque-Ramírez M, Zatik J, Regidor PA.   +7 more
europepmc   +1 more source